<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0004420'>Arterial thrombosis</z:hpo> plays a critical role in <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndromes and <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, the ability to detect <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in vivo has a significant clinical implication </plain></SENT>
<SENT sid="2" pm="."><plain>Magnetic resonance imaging (MRI) has shown promise in noninvasive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> detection </plain></SENT>
<SENT sid="3" pm="."><plain>However, <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> characterization and age definition remain difficult </plain></SENT>
<SENT sid="4" pm="."><plain>We sought to evaluate the use of a fibrin-targeted <z:chebi fb="7" ids="16670">peptide</z:chebi> (EP-2104R) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> detection and to compare this modality with non-contrast-enhanced (NCE) MRI and with Gd-<z:chebi fb="0" ids="35739">DTPA</z:chebi> injection at various ages and time points after <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> generation </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS AND RESULTS: Carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> was induced by external injury and stasis in 18 rabbits </plain></SENT>
<SENT sid="6" pm="."><plain>T1-weighted MRI was performed before and after contrast agent injection, within 6 hours of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> induction, at 48 hours, at 1 week, and every week up to 8 weeks after injury </plain></SENT>
<SENT sid="7" pm="."><plain>Correlation with histopathology was performed </plain></SENT>
<SENT sid="8" pm="."><plain>The fibrin-targeted contrast agent accurately detected <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e>, regardless of their size, location, and age </plain></SENT>
<SENT sid="9" pm="."><plain>Although <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> signal intensity after injection decreased with <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> age (P&lt;0.001), enhancement at 8 weeks was still present </plain></SENT>
<SENT sid="10" pm="."><plain>Gd-<z:chebi fb="0" ids="35739">DTPA</z:chebi> injection was not associated with an improvement of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> detection </plain></SENT>
<SENT sid="11" pm="."><plain>EP-2104R was superior to both NCE and Gd-<z:chebi fb="0" ids="35739">DTPA</z:chebi> injection (P&lt;0.001) </plain></SENT>
<SENT sid="12" pm="."><plain>Histopathologic examination showed <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> organization over time </plain></SENT>
<SENT sid="13" pm="."><plain>Fibrin was gradually replaced by fibrous tissue </plain></SENT>
<SENT sid="14" pm="."><plain>A strong correlation was found between <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> enhancement and collagen content of the organizing <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> with time (R=-0.89; P&lt;0.001) </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: In an experimental animal model of carotid <z:mp ids='MP_0005048'>thrombosis</z:mp>, we have demonstrated the superiority of a fibrin-targeted <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> contrast agent for in vivo detection of <z:hpo ids='HP_0011010'>chronic</z:hpo> or organized <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>, compared with NCE MRI and Gd-<z:chebi fb="0" ids="35739">DTPA</z:chebi> injection </plain></SENT>
</text></document>